Two metres or one: what is the evidence for physical distancing in covid-19?
NR Jones, ZU Qureshi, RJ Temple, JPJ Larwood… - bmj, 2020 - bmj.com
… Jessica PJ Larwood, medical student4, … Jones NR, Qureshi ZU, Temple RJ, Larwood
JPJ, Greenhalgh T, Bourouiba L et al. … Articles by Jessica PJ Larwood …
JPJ, Greenhalgh T, Bourouiba L et al. … Articles by Jessica PJ Larwood …
Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial
…, KRW Emary, DJ Phillips, J Hay, JPJ Larwood… - medRxiv, 2024 - medrxiv.org
Background For pathogens which cause infections that present asymptomatically, evaluating
vaccine efficacy (VE) against asymptomatic infection is important for understanding a …
vaccine efficacy (VE) against asymptomatic infection is important for understanding a …
It doesn't add up: where are the training jobs for double the number of medical students?
JPJ Larwood - bmj, 2022 - bmj.com
As a foundation doctor, I was relieved to hear the Labour party lay out plans for NHS workforce
expansion. 1 But I am concerned by the promise to double the number of medical school …
expansion. 1 But I am concerned by the promise to double the number of medical school …
[HTML][HTML] The Centre for Evidence-Based Medicine
BACKGROUND It is well established that respiratory viruses can be transmitted via viral-laden
mucosalivary respiratory droplets. These are expelled during exhalation, speech, and …
mucosalivary respiratory droplets. These are expelled during exhalation, speech, and …
What is the impact of climate change on infectious disease?
JPJ Larwood - The British Student Doctor …, 2020 - … .thebsdj.cardiffuniversitypress.org
The world is warming at an alarming rate; in October 2018 the Intergovernmental Panel on
Climate Change reported a 1 C human-induced warming since the pre-industrial period and …
Climate Change reported a 1 C human-induced warming since the pre-industrial period and …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa …
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[CITATION][C] Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial (preprint)
L Williams, KRW Emary, D Phillips, J Hay, JPJ Larwood… - 2024
